A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

BACKGROUND: Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating hospital-acquired/ventilator-associated bacterial p...

Descripción completa

Detalles Bibliográficos
Autores principales: Titov, Ivan, Wunderink, Richard G, Roquilly, Antoine, Rodríguez Gonzalez, Daniel, David-Wang, Aileen, Boucher, Helen W, Kaye, Keith S, Losada, Maria C, Du, Jiejun, Tipping, Robert, Rizk, Matthew L, Patel, Munjal, Brown, Michelle L, Young, Katherine, Kartsonis, Nicholas A, Butterton, Joan R, Paschke, Amanda, Chen, Luke F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662781/
https://www.ncbi.nlm.nih.gov/pubmed/32785589
http://dx.doi.org/10.1093/cid/ciaa803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662781/
https://www.ncbi.nlm.nih.gov/pubmed/32785589
http://dx.doi.org/10.1093/cid/ciaa803

Ejemplares similares